#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Alem Truneh Email
Co-Founder & Advisor at Imcheck Therapeutics . Imcheck Therapeutics
Marseille,
Locationa******@imchecktherapeutics.com
Primary EmailHow to contact Alem Truneh
Join and see Alem's contact info for free!Current Roles
Employees:
61Revenue:
$9.5MAbout
ImCheck Therapeutics is designing and developing a new generation of immunotherapy antibodies positioned at the crossroads of two high-potential immunological fields: γ9δ2 T cells and a novel super-family of immunomodulators, butyrophilins. Due to their mechanism of action, and notably their ability to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class†activating antibodies may be able to produce superior anti-cancer efficacy as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, overcome the resistance to this class of agents. Activated γ9δ2 T cells also have therapeutic potential in infectious diseases (e.g., bacteria and viruses), while antagonist antibodies have potential as treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.Imcheck Therapeutics Address
31 chemin Joseph Aiguier CS 70071Marseille, null